HTA
ENZN

Haber Trilix Advisors’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Haber Trilix Advisors’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$76K Buy
+37,950
New +$111K 0.01% 206

Other funds holding ENZN

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Haber Trilix Advisors's ENZN Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in ENZON PHARMACEUTICALS INC (ENZN) in Q2 2013: 37,950 shares worth $76K. The stake represents 0.01% of the portfolio and ranks #206 among its holdings.

83 funds tracked by Wall St. Rank hold ENZN as of Q2 2013.

  • Haber Trilix Advisors held 37,950 shares of ENZON PHARMACEUTICALS INC worth $76K as of Q2 2013.
  • ENZON PHARMACEUTICALS INC was a new Haber Trilix Advisors position in Q2 2013.
  • ENZON PHARMACEUTICALS INC made up 0.01% of Haber Trilix Advisors's portfolio in Q2 2013, its #206 holding.
  • 83 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.